As December draws to a close and Christmas arrives, investors are pausing to look back and assess a year that never followed ...

For decades, geneticists have known that most common illnesses are not caused by a single rogue gene but by intricate ...

Explore the role of patient-derived biology in enhancing antibody-drug conjugates for more effective cancer treatment.

Studienergebnisse DiNAQOR and Academic Partners Launch Paradigm Shift in In Vivo Delivery of Advanced Therapies 23.12.2025 / 14:36 CET/CEST ...

A single dose of Immutep’s MS therapy, IMP761, was well tolerated and reduced T-cell activity for up to 23 days in healthy ...

While artificial intelligence still dominated the industry, there were a couple of breakthroughs that defined the year ...

Ribosomes—the tiny factories that build proteins in our cells—don't all work with the same efficiency. Researchers from Japan have discovered that ...

Seasoned Biotech Entrepreneur Dr. Christian Thirion Appointed CEO of DiNATEQ AG and Group Chief Strategy & Business Development Officer; Dr. Josef El Andari Named Chief Scientific Officer of DiNAQOR ...

Biopharma may see a happier year ahead in 2026 than in recent years, according to analysts at William Blair. For one thing, the industry’s top stocks have recovered from lows that stretched into last ...

Hematologists and oncologists from UC San Francisco shared research results and clinical guidance at the world’s premier meeting for malignant and non-malignant hematology at the American Society of ...

Through a recent notice, the Undergraduate Medical Education Board (UGMEB) of the National Medical Commission (NMC) has ...

JAX and the NYSCF celebrated the official launch of their unified organization with a ribbon-tying ceremony at NYSCF’s Manhattan research facilities.